Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent or Persistent Endometrial Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00723255
What this trial is testing

Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

Who this might be right for
Recurrent Endometrial Carcinoma
National Cancer Institute (NCI) 53
Not applicableWithdrawnNCT01888562
What this trial is testing

Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma

Who this might be right for
Endometrial Neoplasms
Washington University School of Medicine
Early research (Phase 1)Study completedNCT01652794
What this trial is testing

Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer

Who this might be right for
Leydig Cell TumorOvarian SarcomaOvarian Stromal Cancer+10 more
Case Comprehensive Cancer Center 12
Testing effectiveness (Phase 2)Study completedNCT00096447
What this trial is testing

Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Who this might be right for
Recurrent Endometrial Carcinoma
National Cancer Institute (NCI) 31
Testing effectiveness (Phase 2)Study completedNCT00050440
What this trial is testing

Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma

Who this might be right for
Endometrial NeoplasmsUterine NeoplasmsGenital Neoplasms, Female Urogenital Neoplasms
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 50
Testing effectiveness (Phase 2)Study completedNCT01455493
What this trial is testing

GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Who this might be right for
Endometrial Carcinoma
Genentech, Inc. 56
Testing effectiveness (Phase 2)Study completedNCT02728258
What this trial is testing

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Who this might be right for
Endometrial Endometrioid AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous Adenocarcinoma+3 more
NRG Oncology 11
Testing effectiveness (Phase 2)UnknownNCT02064725
What this trial is testing

Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA

Who this might be right for
Recurrent or Persistent Endometrial Carcinoma
Kevelt AS 8
Testing effectiveness (Phase 2)Ended earlyNCT03077698
What this trial is testing

An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

Who this might be right for
Endometrial Cancer
Xenetic Biosciences, Inc. 25
Testing effectiveness (Phase 2)Study completedNCT00085332
What this trial is testing

Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)

Who this might be right for
Endometrial Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Active Not RecruitingNCT03348631
What this trial is testing

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Who this might be right for
Recurrent Endometrial Endometrioid AdenocarcinomaRecurrent Malignant Uterine Corpus NeoplasmRecurrent Ovarian Carcinoma+2 more
National Cancer Institute (NCI) 62
Testing effectiveness (Phase 2)Study completedNCT00267488
What this trial is testing

Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer

Who this might be right for
Neoplasms, EndometrialEndometrial Cancer
GlaxoSmithKline 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT05554328
What this trial is testing

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Who this might be right for
Recurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+1 more
National Cancer Institute (NCI) 165
Testing effectiveness (Phase 2)UnknownNCT02188550
What this trial is testing

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

Who this might be right for
Ovarian CancerEndometrial Cancer
Sinai Hospital of Baltimore 20
Testing effectiveness (Phase 2)Study completedNCT00087100
What this trial is testing

Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer

Who this might be right for
Endometrial Cancer
Gynecologic Oncology Group 51
Testing effectiveness (Phase 2)Study completedNCT00025467
What this trial is testing

Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer

Who this might be right for
Endometrial AdenoacanthomaEndometrial AdenocarcinomaEndometrial Adenosquamous Cell Carcinoma+3 more
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Study completedNCT01011933
What this trial is testing

Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Who this might be right for
Endometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaEndometrial Clear Cell Adenocarcinoma+1 more
National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)Study completedNCT02899793
What this trial is testing

Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

Who this might be right for
Recurrent Endometrial Cancer
Yale University 25
Testing effectiveness (Phase 2)Study completedNCT00377520
What this trial is testing

A Trial for Patients With Advanced/Recurrent Endometrial Cancer

Who this might be right for
NeoplasmsNeoplasms by SiteUrogenital Neoplasms+8 more
Eli Lilly and Company 27
Testing effectiveness (Phase 2)Study completedNCT00004915
What this trial is testing

Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer

Who this might be right for
Endometrial Cancer
Northwestern University
Next Page